PAMELA SEYMOUR: Open Payments
NPI 1568820587 · ADA, OK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$455 in 28 payments from 10 companies in 2025. Trend: 2023 $153 · 2024 $154 · 2025 $455
Food & beverage: $455
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 9 | $124 |
| Novo Nordisk Inc | 3 | $65 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $61 |
| AstraZeneca Pharmaceuticals LP | 3 | $47 |
| GlaxoSmithKline, LLC. | 2 | $41 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $32 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $28 |
| VERTEX PHARMACEUTICALS INCORPORATED | 1 | $23 |
| Averitas Pharma Inc. | 1 | $17 |
| Phathom Pharmaceuticals, Inc. | 2 | $17 |
Products named: MOUNJARO, Kerendia, JARDIANCE, Ozempic, TRELEGY ELLIPTA, CAPLYTA, JOURNAVX, Rybelsus.
Industry payments across OK — which companies pay providers there.
